MedTrace Logo

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

NCT00603772 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-05-06

No results posted yet for this study

Summary

To assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge.

Conditions

  • Healthy

Interventions

DRUG

Atralin (tretinoin) gel, 0.05%

Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.

Sponsors & Collaborators

  • Coria Laboratories, Ltd.

    lead INDUSTRY

Principal Investigators

  • Joseph W Stanfield, MS · Suncare Research Laboratories

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603772 on ClinicalTrials.gov